The Role of Predicitve Factors Over Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon alfa 2a  by Gaseva, M. et al.
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e425
of these anti-HCV positive cases; and to identify any rela-
tionships with injecting behaviours.
Methods: A community-based HCV survey was conducted
in methadone clinics in Hong Kong in 2006. Only injectors
were included. Demographics and drug use pattern were
collected through a questionnaire survey. Blood were col-
lected for anti-HCV tests. RT PCR on NS5B region was then
performed for anti-HCV positive cases.
Results: Serums of 393 anti-HCV positive IDU were avail-
able for genotyping. About 70% (273) were HCV RNA positive;
the rate is higher in male (78%) than female (48%). Alto-
gether the commonest genotype was 6a (143, 52%), followed
by 1b (104, 38%) and 3a (13, 5%). Genotypes 2a, 3b, 6h were
also detected. Genotype 1b became less common among
those started injection more recently and those reported
to have continued sharing injecting equipments in the last
decade. A trend for greater diversity was observed. There
is no discernable difference noted in genotype distribution
regarding injections history in various parts of China and
Hong Kong.
Discussion: Both subtype 1b and 6a have been circulating
among IDU in Hong Kong in the 60s and 70s. In subse-
quent decades genotype 1b has become less dominant while
genotype 3a is getting more common especially among the
younger injectors, an observation similarly reported in China
and elsewhere during growth of IDU epidemic in the 80s.
These sequences will be valuable for evolutionary analy-
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Background: The introduction of pegylated interferon
alfa 2a with ribavirin in therapy of chronic hepatitis C
(CHC) has increased the sustained virological response (SVR)
deﬁned as undetectable HCV RNA sixmonths post treatment.
SVR depends on virus (genotype, viral load) and patient asso-
ciated factors (age, sex, obesities, cirrhosis).
Aim: To evaluate the role of predictive factors: genotype,
viral load and demographic characteristic, age and sex, over
SVR in patients with CHC.
Material and Methods: 75 patients with histological con-
ﬁrmed CHC, positive anti HCV and HCV RNA, were treated at
the Clinic for Infectious Diseases. 53 males and 22 females
from 20 to 66 years of age were divided into two groups:
under vs. above 40 years (55 vs. 20 patients). 41 patients
were with genotype 1 and 33 non-1 genotype (2 genotype 2,
32 genotype 3). Quantitative PCR (Roche Amplicor HCV Test
v 2,0) during the screening protocol quantiﬁed the HCV RNA
level over vs. below 600.000 IU/ml (36 HLV, 39 LVL) Qualita-
tive PCR was performed 6 months after therapy. Patients
received peginterferon alfa-2a (40KD) 180g/weekly and
ribavirin 800/1000/1200mg/d according to genotype.
Results: The overall SVR rate in treated group was 80,0%
(60/75). SVR in patients with genotype 1 was 70,7% (29/41)
and in non-1 genotype 91,2% (31/34) (p = 0,028). SVR in
patients with HVL was 83,3% (30/36) and 84,6% (33/39)
with LVL (p = 0,880). 43/53 (81,1%) male patients and 17/22
(77,3%) female patients had SVR (p = 0,704). In young group
SVR was 89,0% (49/55) and in older than 40 years 55,0%.
(11/20) (p = 0,001).
Conclusion: The efﬁcacy of pegylated interferon alfa 2a
and ribavirin in therapy of CHC was conﬁrmed in our patients
as well. Signiﬁcantly higher SVR rates were obtained in non-1
genotype patients and in younger population group, regard-
less of the sex. Patients infected with genotype 1 and older
patients require individual approach and speciﬁc evaluation
concerning the rapid and early virological response.
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Aims: To study the quantity and quality of HBV-speciﬁc
T cells in chronic hepatitis B (CHB) patients with different
HBeAg status, and to investigate the extent of liver damage
between HBeAg(+) and HBeAg(−) CHB patients.
Methods: A total of 103 CHB patients were selected and
divided into two groups according to the HBeAg status.
The serum HBV markers, liver damage (necroinﬂamma-
tion gradation) were analyzed. The frequency and Foxp3
expression of CD4+CD25+ regulatory T cells (Treg), the HBV-
pentamer(+) T cell frequency and the expression levels of
PD-1, CTLA-4 on HBV-speciﬁc T cells were measured. HBV
antigens speciﬁc T-cell responses including cellular prolifer-
ation and IFN-  production, with or without anti-PD-1 mAb
and/or anti-CTLA-4 mAb blocking, were also tested in vitro
Results: The demographic characters, serum ALT levels,
the frequency and Foxp3 expression of Treg were sim-
ilar between HBeAg(+) and HBeAg(−) patients, and the
serum HBV DNA levels were higher in HBeAg(+) patients
(P < 0.05). The liver necroinﬂammation was comparatively
severe in HBeAg(−) patients (P = 0.052), while the median
percentage of liver cirrhosis was much higher in HBeAg(+)
patients (P < 0.05). The difference of HBV-speciﬁc T-cell fre-
quency was not signiﬁcant between HBeAg(+) and HBeAg(−)
patients, whereas the expression levels of PD-1 and CTLA-
4 on HBV-pentamer(+) T cells were signiﬁcantly higher
in HBeAg(+) patients (P both < 0.05). Combined using of
anti-PD-1 and anti-CTLA-4 mAb could signiﬁcantly increase
